Overview

Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor used in ALK-positive non-small cell lung cancer. Like all targeted agents, it delivers strong initial responses that are eventually limited by drug resistance. Understanding how resistance arises, and which alterations a given inhibitor can or cannot overcome, is central to planning sequential therapy. This article reviews the resistance landscape relevant to ALK inhibitors and the role of next-line options such as lorlatinib.

How Resistance to ALK Inhibitors Emerges

Resistance to ALK TKIs follows several routes. The most studied is the acquisition of secondary mutations in the ALK kinase domain, which alter drug binding; examples include L1196M, G1269A, I1171 substitutions and solvent-front changes such as G1202R. Bypass signaling through other receptors (for instance EGFR, KRAS or MET activation), ALK gene amplification, epithelial-to-mesenchymal transition and histologic transformation to small-cell lung cancer represent additional escape mechanisms. Critically, different inhibitors vary in which mutations they overcome: ceritinib retains activity against several crizotinib-resistance mutations but shows limited activity against the G1202R solvent-front mutation and F1174C.

ALK rearrangements account for roughly 3 to 5 percent of NSCLC, making resistance management in this subgroup a deeply studied field that has produced the mutation map now guiding sequential therapy.

Sequential Therapy After Resistance

When resistance develops, repeating biopsy or liquid biopsy to identify the specific alteration guides the next choice. Because the G1202R mutation is refractory to most first- and second-generation ALK TKIs, including crizotinib and ceritinib, the third-generation inhibitor lorlatinib, which was designed to retain activity against G1202R and many compound mutations, becomes a rational next step. For resistance driven by bypass pathways, combination strategies targeting the activated route may be explored in trial or experienced-center settings. The key takeaway is that resistance is not uniform, and mutation-guided sequencing improves the odds of sustained disease control. After several prior ALK TKIs, compound mutations can emerge that even limit lorlatinib, which is why the optimal first-line agent remains actively debated among experts.

FAQ

Q: Can ceritinib overcome the G1202R ALK mutation? A: No. Published preclinical and clinical evidence shows ceritinib has limited activity against the G1202R solvent-front mutation; lorlatinib is the agent that retains activity against it.

Q: Besides mutations, how else do tumors evade ALK inhibitors? A: Resistance can arise through bypass signaling (EGFR, KRAS, MET), ALK amplification, EMT and histologic transformation to small-cell lung cancer.

Q: Why repeat biopsy at progression? A: Rebiopsy or liquid biopsy can reveal the specific resistance alteration, which determines whether a next-generation ALK TKI or a combination approach is most appropriate.